Enable AccessibilityEnable Accessibility

Takeda’s global acquisition of Shire creates an expanded Takeda Canada to bring better health and a brighter future to Canadians

January 10, 2019

Takeda in Canada headed by General Manager Gamze Yüceland

An expanded footprint positions Takeda to provide innovative treatments for Canadians
with gastrointestinal illnesses, cancer, neurological conditions and rare diseases


Oakville, Ontario  – The global acquisition by Takeda of Shire has been completed and with it comes the creation of an expanded Takeda Canada organization that unites the operations of the two pharmaceutical companies.

The combined company will be headed by General Manager, Gamze Yüceland.

“I am very pleased that Gamze Yüceland will be heading the operations of Takeda Canada in the combined organization,” said Giles Platford, President of the Takeda Europe & Canada (EUCAN) Business Unit. “We have exciting opportunities through our new, larger organization in Canada to do even more for Canadian patients, bringing transformative therapies and, making a positive impact on their lives”.

The expanded Takeda Canada builds on the distinctive strengths and core therapeutic areas of both companies and aspires to be best-in-class, a preferred partner for customers and above all, the most patientcentric organization.

“Shire has been an important presence in Canada, particularly for Canadians facing the considerable challenges of dealing with neurological conditions and rare diseases,” said Ms. Yüceland. “In collaboration with our new colleagues, we will continue to maximise our presence in gastroenterology and oncology to make the most of the complementary strengths of both organizations. As always, we will put the patient at the centre of our activities and will continue to be guided by our values and empower our people to shine.”

Takeda is focused on a smooth integration. For the immediate future, the company will continue to operate from the Takeda Canada offices in Oakville, Ontario, and the former Shire Canada offices in downtown Toronto. Canadian head office teams will eventually be united in one location.

Healthcare professionals, stakeholders and patients should continue to use current phone numbers and procedures to order products or to seek medical or safety information regarding products.

Globally, Takeda remains headquartered in Japan and now has an attractive, expanded geographic footprint, bringing its highly-innovative medicines to more than 80 countries/regions with dedicated employees worldwide. The combined company will deliver highly-innovative medicines and transformative care to more people around the world than ever before. The company’s world-class R&D engine is stronger than ever, with a highly complementary, robust, modality-diverse pipeline. R&D efforts are now focused on four therapeutic areas – oncology, gastroenterology, neuroscience, and rare diseases, with some specific R&D investment also committed to plasma-derived therapies and vaccines.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502) (NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

About Takeda Canada
Takeda Canada headquarters is currently located in Oakville, Ontario. The Oakville and Toronto offices comprise the Canadian sales and marketing organization of Takeda Pharmaceutical Company Limited. Takeda Canada is delivering better health for Canadians through leading innovations in gastroenterology, oncology, neuroscience, and rare diseases. Additional information about Takeda Canada is available at takeda.com/en-ca.